AKEBIA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
AKEBIA THERAPEUTICS, INC. (AKBA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -18.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -18.30%.
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was 0.00%.
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 0.00%.
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 0.00%, a 100.00% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -18.30% 10-K · filed 2026-02-26 | |
| 2020-12-31 | 0.00% 10-K · filed 2021-02-25 | |
| 2019-12-31 | 0.00% 10-K · filed 2021-02-25 | |
| 2018-12-31 | 0.00% 10-K · filed 2021-02-25 | |
| 2017-12-31 | 0.60% 10-K · filed 2020-03-12 | |
| 2016-12-31 | 0.20% 10-K · filed 2019-03-26 | |
| 2015-12-31 | 0.60% 10-K · filed 2018-03-12 | |
| 2014-12-31 | 1.60% 10-K · filed 2017-03-06 | -1.60% 10-K · filed 2015-03-04 |
| 2013-12-31 | -2.60% 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |